Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apligraf Reduces Healing Time For Diabetic Foot Ulcers By 30%

This article was originally published in The Gray Sheet

Executive Summary

Organogenesis' Apligraf living skin construct reduces the time it takes diabetic foot ulcers to heal by almost one-third, the company says.

You may also be interested in...



Organogenesis Predicting Apligraf Approval For Diabetic Ulcers In Early 2000

Organogenesis plans to file a premarket approval application supplement in late 1999 that would expand the indications for its Apligraf living skin graft to include diabetic foot ulcers, Chief Strategic Officer Alan Tuck told the New York Society of Security Analysts March 16 in New York.

ATS' Dermagraft

Treatment investigational device exemption for the bioengineered human skin graft in the treatment of diabetic foot ulcers is approved by FDA, according to Advanced Tissue Sciences, which says it will focus on a "small number of centers" while working with the Health Care Financing Administration and other payers to address reimbursement. The treatment IDE study will be conducted concurrently with the firm's ongoing clinical trial ("The Gray Sheet" Aug. 10, In Brief). FDA requested the additional study in June to support the firm's premarket approval application for Dermagraft ("The Gray Sheet" June 15, p. 5)

Organogenesis Apligraf U.S. Shipments By Novartis To Begin In June

Organogenesis Apligraf skin graft shipments are scheduled to begin in June following FDA approval May 22 for treatment of venous ulcers.

Related Content

UsernamePublicRestriction

Register

MT012213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel